28 June 2019
28 June 2019
("Physiomics") or (the "Company")
Physiomics signs agreement with Bicycle Therapeutics to support immune-oncology program
Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to announce that it has been awarded a contract by Bicycle Therapeutics plc (Nasdaq: BCYC) ("Bicycle"). The project will focus on the mathematical computer modelling of interactions between tumour and Bicycle(R) compounds in an immune-oncology setting. This will be the fourth project conducted by Physiomics in the immune-oncology space and highlights the Company's rapidly developing capabilities in an area that is currently receiving significant investor and scientific focus.
Dr Jim Millen, CEO said: "We are thrilled to be working with Bicycle Therapeutics, which we believe to be one of the UK's most exciting emerging biotech companies."
Dr Jim Millen, CEO
+44 (0)1865 784 980
Strand Hanson Ltd (NOMAD)
Richard Tulloch & James Dance
+44 (0)20 7409 3494
Hybridan LLP (broker)
Claire Louise Noyce
+44 (0)20 3764 2341
Notes to Editor
Physiomics plc (AIM: PYC) is a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry. The Company's Virtual Tumour(TM) technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 70 projects, involving over 30 targets and 60 drugs, and has worked with clients such as Merck KGaA, Merck & Co, Bayer and Lilly.
Based in Oxford UK, the Company works with clients worldwide to support their pre-clinical and clinical oncology development programs. Its team of scientists and computer modelling experts provide bespoke solutions encompassing data, analytics and insight.
Physiomics senior management has academic and commercial expertise, including over 120 years collectively of working in oncology and/or computational biology and over 120 publications in peer reviewed journals that have attracted thousands of citations.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact email@example.com or visit www.rns.com.
(END) Dow Jones Newswires
June 28, 2019 02:01 ET (06:01 GMT)